Novo Holdings

08.02.2024 • News

Novo Holdings to Acquire Catalent for $16.5 Billion

Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said that Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Top-Feature

Evonik Operations GmbH (Hanau)

Biobased Feedstocks as a Roadmap to Defossilization

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Free Virtual Event

Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Catalent Inc.